ERBB2 and neoplasm: Monoclonal antibodies targeting HER2 recognize HER2 antigens via their Fab segment and attach to immune cells through their Fc segment, thereby performing anti-tumor functions by means of antibody-dependent cell cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC) (22, 23).